hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06367543 id: AZ 117/22 briefTitle: Guideline-recommended Basic Parameter Adherence in Neurocritical Care Patients acronym: NORMONICU overallStatus: ACTIVE_NOT_RECRUITING date: 2022-11-30 date: 2024-02-29 date: 2024-12-31 date: 2024-04-16 date: 2024-04-16 name: University of Giessen class: OTHER name: University of Leipzig name: University of Wuerzburg name: Technical University of Munich name: Heidelberg University name: University of Cologne name: University of Mannheim name: University Hospital, Essen briefSummary: The aim of the planned study project is to assess the current situation regarding the treatment of patients with severe stroke at the neuro-critical care unit. Specifically, determination of whether the target parameters recommended in the guidelines for temperature, systolic blood pressure, mean arterial blood pressure, blood glucose, arterial oxygen partial pressure and arterial carbon dioxide partial pressure had to be maintained. From the planned data analysis, the need for the introduction of cerebrovascular bundles can be derived and planned. conditions: Stroke studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 474 type: ACTUAL name: Time in therapeutic range of vital parameters measure: Time in Therapy range measure: Acute measures measure: Invasive measures performed in the course of the Stay measure: Duration of ventilation measure: Deceased on Intensive Care. measure: NIHSS (National Institutes of Health Stroke Scale). sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Universitätsklinikum Gießen city: Gießen state: Hessen zip: 35392 country: Germany lat: 50.58727 lon: 8.67554 hasResults: False
nctId: NCT06367530 id: GS-TRIO-2024 briefTitle: Trilateral Retinoblastoma: Incidence and Outcomes acronym: GS-TRIO overallStatus: RECRUITING date: 2024-01-01 date: 2027-12-31 date: 2029-12-31 date: 2024-04-16 date: 2024-04-16 name: Amsterdam UMC, location VUmc class: OTHER briefSummary: Patients with heritable retinoblastoma are at risk to develop an intracranial brain tumor, which is often fatal. The investigators intend to look at the incidence and survival of trilateral retinoblastoma (which is a brain tumor that can either be located in the pineal gland or elsewhere in the brain) in retinoblastoma patients globally. All retinoblastoma patients from participating centers will be included. The investigators hypothesize that the apparent incidence of trilateral retinoblastoma (especially the usually later diagnosed pineal trilateral retinoblastoma) in low-income countries will be lower because of low chances of surviving the ocular tumors at about 50% and also because of possible under-diagnosis. Therefore, as retinoblastoma care improves in low-income countries the incidence of (pineal) trilateral retinoblastoma might go up. Knowledge about incidence and survival can help improve health practices in parts of the world where this might be needed. Therefore this global study firstly aims 1) to evaluate survival after trilateral retinoblastoma and factors influencing survival and 2) to evaluate incidence of trilateral retinoblastoma by country income level. The study will run from 2024 through 2027. conditions: Trilateral Retinoblastoma conditions: Retinoblastoma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 4351 type: ESTIMATED name: Incidence and survival of trilateral retinoblastoma and the differences globally measure: Number of participants (retinoblastoma patients) that will be diagnosed with trilateral retinoblastoma (incidence) measure: Overall and event-free survival after being diagnosed with trilateral retinoblastoma sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Amsterdam UMC status: RECRUITING city: Amsterdam state: Noord-Holland zip: 1082HV country: Netherlands name: Pim de Graaf, MD PhD role: CONTACT phone: 800-555-5555 email: p.degraaf@amsterdamumc.nl lat: 52.37403 lon: 4.88969 hasResults: False
nctId: NCT06367517 id: KB/114/2022 briefTitle: Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease) overallStatus: RECRUITING date: 2021-05-20 date: 2025-05-20 date: 2026-05-20 date: 2024-04-16 date: 2024-04-16 name: Medical University of Warsaw class: OTHER briefSummary: The aim of this study is to evaluate the efficacy and safety of Tocilizumab as second/third line treatment in patients with Active Moderate-to-Severe Corticosteroid-Resistant Thyroid Eye Disease. conditions: Orbitopathy, Graves conditions: Thyroid Eye Disease conditions: Ophthalmopathy studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 30 type: ESTIMATED name: Tocilizumab measure: Disease improvement measure: Improvement of quality of life measure: Disease inactivation measure: Proportion of patients achieving response in specific GO signs and symptoms measure: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 measure: Decrease in concentration of thyrotropin receptor antibodies measure: Decrease in levels of proinflammatory cytokines measure: Number of the rehabilitative surgeries performed after immunosuppressive therapy measure: The rate of disease relapse measure: Decrease in proptosis by at least 2 mm assessed using magnetic resonance imaging (MRI) sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Internal Medicine and Endocrinology, Medical University of Warsaw status: RECRUITING city: Warsaw zip: 02-097 country: Poland name: Tomasz Bednarczuk, MD, PHD role: CONTACT email: tomasz.bednarczuk@wum.edu.pl name: Joanna Rymuza, MD, PHD role: CONTACT email: joanna.rymuza@wum.edu.pl name: Tomasz Bednarczuk, MD, PHD role: PRINCIPAL_INVESTIGATOR name: Joanna Rymuza, MD, PHD role: SUB_INVESTIGATOR name: Aleksander Kuś, MD, PHD role: SUB_INVESTIGATOR lat: 52.22977 lon: 21.01178 hasResults: False
nctId: NCT06367504 id: DB/230904/DBMF/CDI briefTitle: A Study to Assess the Effect of Doctor's Biome Medical Food in Individuals With Clostridium Difficile Infection overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-12-15 date: 2024-12-30 date: 2024-04-16 date: 2024-04-16 name: Vedic Lifesciences Pvt. Ltd. class: INDUSTRY briefSummary: A randomized, double-blind, placebo-controlled, pilot clinical study to assess the effect of Doctor's Biome Medical Food (DBMF) in individuals with Clostridium difficile infection (CDI) conditions: Clostridium Difficile Infection studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized, parallel group, double-blind, placebo-controlled trial primaryPurpose: OTHER masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 20 type: ESTIMATED name: DBMF name: Placebo measure: To evaluate the effect of Investigational product on the duration of Clostridium difficile diarrhea in comparison to placebo. measure: To assess the impact of the Investigational product on Number of CDI diarrhea episodes presence of Clostridium difficile in stool samples as assessed by C. difficile toxins A & B - CARD. measure: To assess the impact of the Investigational product on Change in the frequency of watery stools from Bristol Stool Form Scale (BSFS) score type 7 as compared to placebo. measure: To assess the impact of the Investigational product on Number of non-CDI diarrhea episodes as compared to placebo measure: To assess the impact of the Investigational product on Number of SOC medication consumed (antibiotics therapy) throughout the intervention period as compared to placebo. measure: To assess the impact of the Investigational product on Average number of days of consumption of SOC (antibiotics therapy) as compared to placebo. sex: ALL minimumAge: 30 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: AIMS Hospital city: Dombivali state: Maharashtra zip: 421203 country: India name: Dr Sandeep Kardian, MBBS MD role: CONTACT phone: 870364574 email: sandeepkadian@rediffgmail.com lat: 19.21667 lon: 73.08333 facility: Stress Test Clinic city: Mumbai state: Maharashtra zip: 400059 country: India name: Dr Ramesh Dargad, MBBS MS role: CONTACT phone: 9820152828 email: rohitdargad@outlook.com lat: 19.07283 lon: 72.88261 facility: Nobel Hospital city: Pune state: Maharashtra zip: 411013 country: India name: Dr Pramod Katare, MBBS MD role: CONTACT phone: 8830793201 email: drkatareps@gmail.com lat: 18.51957 lon: 73.85535 facility: Gleneagles Hospital city: Hyderabad state: Telangana zip: 500004 country: India name: Dr G S Sameer Kumar, MBBS MD role: CONTACT phone: 8860031692 email: sameerzidane@gmail.com lat: 17.38405 lon: 78.45636 hasResults: False
nctId: NCT06367478 id: SPEMG briefTitle: Evaluation of Nerve Conduction Study acronym: SPEMG overallStatus: ACTIVE_NOT_RECRUITING date: 2021-08-01 date: 2021-10-22 date: 2024-10-22 date: 2024-04-16 date: 2024-04-16 name: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico class: OTHER briefSummary: the investigators study different modality to obtain nerve evoked reponses. They use different parameters of acquisition and stimulation and they compare amplitude and latency of nerve conduction response conditions: Nerve Condition conditions: Health, Subjective studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 125 type: ACTUAL measure: best amplitude of nerve conduction study sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico of Milan city: Milan zip: 20122 country: Italy lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06367465 id: 202308056 briefTitle: Feasibility and Acceptability of HCV Treatment in Pregnancy overallStatus: RECRUITING date: 2024-02-01 date: 2026-02-28 date: 2026-02-28 date: 2024-04-16 date: 2024-04-16 name: Washington University School of Medicine class: OTHER briefSummary: Pregnant adults over the age of 18 who are seen in the Washington University obstetrics and gynecology, maternal fetal medicine or infectious diseases clinic or admitted to BJH with hepatitis C virus infection who have a history of past or current drug use
Aim 2 - Evaluate patient experience with hepatitis C virus treatment during pregnancy. conditions: Hepatitis C conditions: Pregnancy Complications studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 50 type: ESTIMATED name: Glecaprevir-pibrentasvir measure: Medication adherence and treatment completion rates. measure: Patient satisfaction Questionnaire measure: Virologic outcome and clinical success at Day 28 post treatment measure: Sample size estimation for future study sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Barnes Jewish Hospital status: RECRUITING city: Saint Louis state: Missouri zip: 63110 country: United States name: Tracey Bach role: CONTACT phone: 314-273-6075 email: habrockt@wustl.edu name: Laura Marks, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 38.62727 lon: -90.19789 facility: Washington Univeristy status: RECRUITING city: Saint Louis state: Missouri zip: 63110 country: United States name: Laura Marks, MD,PhD role: CONTACT email: marks@wustl.edu name: Tracey Habrock-Bach, MBA role: CONTACT phone: 314-273-6075 email: habrockt@wustl.edu lat: 38.62727 lon: -90.19789 hasResults: False
nctId: NCT06367452 id: CAEP 107.001.23 briefTitle: Exploratory Pilot Study to Evaluate the Pharmacokinetic Profile of Magaldrate overallStatus: COMPLETED date: 2023-10-31 date: 2024-01-15 date: 2024-03-30 date: 2024-04-16 date: 2024-04-16 name: Tecnoquimicas class: INDUSTRY briefSummary: The goal of this clinical pilot study is to evaluate the pharmacokinetic profile of magaldrate in a group of 10 healthy women, after the administration of a 10 mL drug suspension containing 500 mg of sodium alginate, 267 mg of sodium bicarbonate, 800 mg of magaldrate and 120 mg of simeticone. The main question it aims to answer is the amount of magnesium and/or aluminum, if any, absorbed into the plasma from this oral administration.
Researchers will compare the levels of both ions in plasma in a group to see if there is any absorption, quantifying the basal plasma levels and comparing with the levels obtained after the meal and the medication, when it applies. conditions: Healthy studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: NONE count: 10 type: ACTUAL name: Sodium alginate + sodium bicarbonate + magaldrate + simeticone measure: Cmax for Aluminum measure: AUC for Aluminum measure: Cmax for Magnesium measure: AUC for Magnesium measure: Amount of aluminum ions absorbed after drug administration vs amount provided by food sex: FEMALE minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: CAEP city: Campinas state: Sao Paulo zip: 13087-567 country: Brazil lat: -22.90556 lon: -47.06083 hasResults: False
nctId: NCT06367426 id: Pharmacobio briefTitle: A Phase I Study of DDN-A-0101 in Healthy Volunteers and Elder People overallStatus: RECRUITING date: 2024-04 date: 2025-05 date: 2025-05 date: 2024-04-16 date: 2024-04-16 name: Pharmacobio class: INDUSTRY briefSummary: The study is a Phase I, randomized double-blind, placebo-controlled, single and multiple dosing, dose-escalation study of the oral administration of DDN-A-0101 in healthy adults and elderly subjects conditions: Alzheimer Disease studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: To maintain double-blindness, DDN-A-0101 tablets and placebo with the same formulation and properties that cannot be distinguished in appearance will be used, and sub-packaging will also be the same. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 100 type: ESTIMATED name: DDN-A-0101 (SAD) name: DDN-A-0101 (MAD) name: Placebo (SAD) name: Placebo (MAD) measure: Assessment of safety and tolerability of DDN-A-0101 by monitoring vital signs measure: Assessment of safety and tolerability of DDN-A-0101 by monitoring vital signs measure: Assessment of safety and tolerability of DDN-A-0101 by monitoring vital signs measure: Assessment of safety and tolerability of DDN-A-0101 by monitoring ECG measure: Assessment of safety and tolerability of DDN-A-0101 by C-SSRS measurement measure: Assessment of safety and tolerability of DDN-A-0101 by laboratory safety tests measure: Assessment of safety and tolerability of DDN-A-0101 by laboratory safety tests measure: Assessment of safety and tolerability of DDN-A-0101 by laboratory safety tests measure: Assessment of pharmacokinetics of Quercitrin, an indicator of of DDN-A-0101 in plasma measure: Assessment of pharmacokinetics of Quercitrin in plasma measure: Assessment of pharmacokinetics of Quercitrin in plasma measure: Assessment of pharmacokinetics of Quercitrin in plasma measure: Assessment of pharmacokinetics of Quercitrin in plasma measure: Assessment of pharmacokinetics of Quercitrin in plasma measure: Assessment of pharmacokinetics of Quercitrin in plasma measure: Assessment of pharmacokinetics of Quercitrin in plasma measure: Assessment of pharmacokinetics of Quercitrin in urine measure: Assessment of pharmacokinetics of Quercitrin in urine measure: Assessment of pharmacokinetics of Quercitrin in urine measure: Assessment of pharmacodynamics of DDN-A-0101 for PART2 MAD test measure: Assessment of pharmacodynamics of DDN-A-0101 for PART2 MAD test sex: ALL minimumAge: 19 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Seoul National University College of Medicine and Hospital status: RECRUITING city: Seoul zip: 03080 country: Korea, Republic of name: In-Jin Jang, Doctor role: CONTACT phone: 82-2-740-8290 email: ijjang@snu.ac.kr lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06367400 id: SwePSQ briefTitle: Validation of Pediatric Sleep Questionnaire on a Swedish Cohort overallStatus: RECRUITING date: 2024-03-01 date: 2024-12-31 date: 2034-12-31 date: 2024-04-16 date: 2024-04-16 name: Uppsala University class: OTHER name: Karolinska Institutet name: Örebro University, Sweden name: Umeå University name: Göteborg University briefSummary: This study is aimed to validate the questionnaire called Pediatric Sleep Questionnaire on a Swedish cohort of children from 18 months to 15 years old with obstructive sleep disordered breathing. conditions: Obstructive Sleep Apnea conditions: Sleep Disorder conditions: Sleep Disorders in Children conditions: Obstructive Sleep Apnea of Child studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 520 type: ESTIMATED name: Pediatric Sleep Questionnaire measure: Level of baseline PSQ measure: Changes of baseline PSQ after treatment measure: PSQ vs OSA-18 measure: PSQ vs. PSG measure: PSQ levels of healthy controls vs children with OSDB measure: 5 and 10 years follow-up sex: ALL minimumAge: 18 Months maximumAge: 15 Years stdAges: CHILD facility: Akademiska hospital status: RECRUITING city: Uppsala country: Sweden name: Isabella Sjölander role: CONTACT phone: 018-6110000 email: isabella.sjolander@uu.se lat: 59.85882 lon: 17.63889 hasResults: False
nctId: NCT06367387 id: STUDY23080191 id: RM1DA055311 type: NIH link: https://reporter.nih.gov/quickSearch/RM1DA055311 briefTitle: Pain Self-Management and Patient-Oriented Dosing for Pain and in Retention Opioid Treatment acronym: TREETOP overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-12 date: 2026-12 date: 2024-04-16 date: 2024-04-16 name: Jessica Merlin class: OTHER name: National Institute on Drug Abuse (NIDA) briefSummary: This study seeks to improve the treatment of chronic pain in people who are taking buprenorphine (also known as Suboxone, Subutex, Zubsolv).
nctId: NCT06367374 id: BGB-11417-2002-IIT；BDH-CLL-004 briefTitle: MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL overallStatus: NOT_YET_RECRUITING date: 2024-05-30 date: 2030-02-28 date: 2030-07-30 date: 2024-04-16 date: 2024-04-16 name: Institute of Hematology & Blood Diseases Hospital, China class: OTHER briefSummary: This is a single-arm, open-label study of sonrotoclax plus zanubrutinib with MRD-driven treatment duration in patients with previously untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).
The primary goal of this study is to evaluate the efficacy of MRD-guided zanubrutinib plus sonrotoclax for first-line CLL/SLL treatment. conditions: Chronic Lymphocytic Leukemia conditions: Small Lymphocytic Lymphoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 66 type: ESTIMATED name: Sonrotoclax name: Zanubrutinib measure: 4-Year Progressive Free Survival (PFS) Rate measure: Rate of peripheral blood (PB) and Bone marrow (BM) undetectable minimal residual disease (uMRD) measure: Complete Response Rate (CRR; Complete Response/Complete Response with Incomplete Blood Count Recovery [CR/CRi]) Rate measure: Overall Response Rate (ORR) measure: Duration of Response (DOR) measure: Progression Free Survival (PFS) measure: Overall Survival (OS) measure: Time to Next Therapy (TTNT) measure: Overall survival rate sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06367361 id: SIDISI 201221 id: U01AI155323 type: NIH link: https://reporter.nih.gov/quickSearch/U01AI155323 briefTitle: One and Two Doses of Oxfendazole Versus a Schedule of Two Doses of Triclabendazole in Chronic Fascioliasis overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2028-03 date: 2028-03 date: 2024-04-16 date: 2024-04-16 name: Universidad Peruana Cayetano Heredia class: OTHER name: National Institute of Allergy and Infectious Diseases (NIAID) briefSummary: Randomized clinical trial comparing the efficacy and safety of oxfendazole at 20 mg/kg per dose in one and two dose regimens with a two-dose regimen of triclabendazole at 10 mg/kg in an endemic region of the highlands of Peru. Children and adults with fascioliasis in rural communities will be screened for inclusion and exclusion criteria and a total of 336 subjects (112 per study arm) with chronic Fasciola infection will be enrolled and assigned randomly to the study arms in a 1:1:1 ratio. The primary efficacy (cure and egg reduction) endpoints will be assessed on day 7 and 30 post treatment. The secondary safety endpoint visits will be performed in days 0, 3, 7 and 30 post-treatment and Population PK modeling studies will be performed in the first 24 hours after the first dose of oxfendazole. conditions: Fascioliasis studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Study arm 1: Oxfendazole 100 mg tablets at 20 mg/kg of body weight as a single oral dose administered with a lipid containing meal under direct observation.
Study arm 3: Triclabendazole 250 mg tablets at 10 mg/kg of body weight per dose in two oral doses separated 24 hours each administered with a lipid containing meal under direct observation. primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: The laboratory personnel processing the stool microscopy tests will be blinded to the treatment assignment. Thus, the intervention will be blinded to the assessors of the primary endpoint. whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 336 type: ESTIMATED name: Oxfendazole name: Triclabendazole measure: Parasitological cure rate of chronic fascioliasis measure: Egg reduction rate day 7 measure: Egg reduction rate day 30 measure: Safety information on day 0 measure: Safety information on day 3 measure: Safety information on day 7 measure: Safety information on day 30 measure: Laboratory safety information day 7 measure: Laboratory safety information day 30 measure: Population pharmacokinetics model constructs for oxfendazole measure: Population pharmacokinetics model constructs for oxfendazole sulfone measure: Population pharmacokinetics model constructs fenbendazole sex: ALL minimumAge: 16 Years maximumAge: 65 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06367335 id: ETIC briefTitle: Characteristics and Predictors of Liver Injury in Cyclin-dependent Kinase Inhibitors 4/6 (CDK4/6)-Treated Patients With Advanced Breast Cancer acronym: ETIC overallStatus: COMPLETED date: 2022-06-01 date: 2022-09-01 date: 2022-12-31 date: 2024-04-16 date: 2024-04-16 name: University of Milano Bicocca class: OTHER briefSummary: The main objective of the study is to evaluate the presence of predictors (single characteristics at the baseline and / or a combination of two or more parameters) useful for predicting the development of Drug-Induced liver Injury (DILI) during treatment with cyclin-dependent kinase inhibitors (CKI) with the possibility of obtaining a pre-treatment prognostic score that can assist the clinician in pre-therapy decision making. conditions: DILI studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 128 type: ACTUAL name: Ribociclib, palbociclib, abemaciclib measure: Incidence of DILI measure: withdrawal of therapy measure: delayed reprise of antineoplastic therapy sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Milano-Bicocca, city: Monza zip: 20900 country: Italy lat: 45.58005 lon: 9.27246 hasResults: False